36 min
PT500 – Shulgin Farm and the Future of Psychedelic Drug Development, with Paul F. Daley, Ph.D. Psychedelics Today
-
- Life Sciences
In this episode, Joe interviews Paul F. Daley, Ph.D., who worked with Sasha Shulgin in his lab for the last seven years of his life, helping him finish (and co-authoring) "The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds."
He is now the co-founder, Chief Science Officer, and Director of Analytical Science at the Alexander Shulgin Research Institute (ASRI), focusing on the discovery and development of novel psychedelic compounds. While Sasha was passionate about self-experimentation, the Institute is aiming for the next step for these drugs: FDA approval.
He discusses:
Meeting Sasha at the 2nd international conference on hallucinogenic mushrooms in Washington D.C. Bonding with Sasha while reviewing the autopsy of researcher Robert van den Bosch for possible foul play The two compounds ASRI is closest to being able to test in clinical trials The 5-HT2B receptor, risk of valvular disease, and why we will likely be hearing more about this going forward How AI and new technology can lead to better safety science and more!
Click here to head to the show notes page.
In this episode, Joe interviews Paul F. Daley, Ph.D., who worked with Sasha Shulgin in his lab for the last seven years of his life, helping him finish (and co-authoring) "The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds."
He is now the co-founder, Chief Science Officer, and Director of Analytical Science at the Alexander Shulgin Research Institute (ASRI), focusing on the discovery and development of novel psychedelic compounds. While Sasha was passionate about self-experimentation, the Institute is aiming for the next step for these drugs: FDA approval.
He discusses:
Meeting Sasha at the 2nd international conference on hallucinogenic mushrooms in Washington D.C. Bonding with Sasha while reviewing the autopsy of researcher Robert van den Bosch for possible foul play The two compounds ASRI is closest to being able to test in clinical trials The 5-HT2B receptor, risk of valvular disease, and why we will likely be hearing more about this going forward How AI and new technology can lead to better safety science and more!
Click here to head to the show notes page.
36 min